1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Otsuka Holdings Co., Ltd.

Otsuka Holdings Co., Ltd.

OTSKF
Otsuka Holdings Co., Ltd.US flagOther OTC
64.57
USD
- -
- -
34.05BMarket Cap
2014 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2,675.48
- -
2,634.32
2,206.42
2,288.37
2,384.4
2,575.59
2,623.61
2,762.43
3,203.35
3,719.59
4,303.37
4,657.41
4,016.77
Basic EPS, GAAP
278.07
- -
188.17
170.83
207.61
152.24
234.55
273.16
231.32
246.81
224.1
633.76
685.06
233.67
Free Cash Flow per Basic Share
288.25
- -
336.54
129.96
46.68
114.82
238.33
248.87
213.34
191.8
310.6
416.1
494.08
306.89
Dividend per Share
60.32
- -
90.77
100.95
101.25
102.05
102.49
102.7
103.22
102.41
102.55
123.31
133.89
112.89
Book Value per Share
1,642.05
- -
2,290.77
2,382.27
2,487.94
2,419.59
2,557.18
2,737.03
2,883.39
3,013.07
3,137.92
3,668.42
4,315.1
3,278.34
Tangible Book Value per Share
2,428.22
- -
1,848.18
1,955.58
2,060.77
1,778.17
1,922.39
2,145.11
2,261.88
2,482.95
2,886.19
3,295.97
3,802.39
3,344.04
Basic Weighted Avg Shares
543
- -
542
542
542
542
542
542
542
543
543
541
530
543
Sales/Revenue/Turnover
1,452,759
- -
1,427,375
1,195,547
1,239,952
1,291,981
1,396,240
1,422,826
1,498,276
1,737,998
2,018,568
2,329,861
2,468,892
2,179,960
Operating Margin (%)
13.68
- -
9.56
7.12
6.84
9.79
12.49
14.87
10.18
10.71
14.45
17.85
19.12
16.22
Depreciation Expense
47,098
- -
59,156
59,574
62,235
59,275
75,690
79,423
84,855
93,761
97,777
107,979
116,167
105,089
Net Income, GAAP
150,989
- -
101,957
92,563
112,492
82,492
127,151
148,137
125,463
133,906
121,616
343,120
363,150
126,816
Effective Tax Rate (%)
27.43
- -
33.88
20.01
- -
22.01
24.39
20.13
21.04
20.63
12.03
- -
21.75
10.24
Profit Margin (%)
10.39
- -
7.14
7.74
9.07
6.38
9.11
10.41
8.37
7.7
6.02
14.73
14.71
5.82
Working Capital
731,421
753,798
660,544
677,242
624,477
505,600
547,460
587,514
581,479
652,837
659,564
734,308
872,894
775,414
LT Debt
19,973
22,660
234,292
193,972
176,961
146,132
188,487
181,878
162,480
150,004
125,915
160,887
166,919
129,383
Total Equity
1,510,759
1,685,662
1,727,369
1,738,441
1,821,949
1,732,265
1,795,439
1,883,432
2,045,189
2,262,369
2,436,317
2,778,164
3,099,761
2,666,772
Return on Invested Capital (%)
9.42
- -
4.68
3.33
- -
4.9
6.55
8.05
5.48
6.21
9.89
- -
11.61
11.2
Return on Capital (%)
16.32
- -
7.57
6.44
- -
5.41
8
9.05
7.07
7.36
6.45
- -
15.88
6.5
Return on Common Equity (%)
18.19
- -
8.4
7.31
8.53
6.2
9.43
10.32
8.23
8.37
7.29
18.6
17
7.27

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
88,272
71,975
118,583
LT Borrowings
69,200
68,673
67,900
LT Finance Leases
56,715
58,818
61,483
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
543
543
543
Market Capitalization
2,997,774
3,152,625
3,449,188

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,326,797
1,305,155
1,499,238
Cash, Cash Equivalents & STI
529,403
476,306
591,052
Accounts Receivable, Net
474,086
469,636
530,612
Inventories
249,581
273,827
296,778
Total Current Liabilities
667,233
631,469
723,824
Payables & Accruals
- -
- -
- -
ST Debt
88,272
71,975
118,583
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.16%
10.5%
11.58%
Free Cash Flow
22.02%
17.51%
16.26%
Net Income, GAAP
22.65%
34.04%
5.84%
Sales/Revenue/Turnover
6.05%
11.77%
5.97%
Total Cash Common Dividend
3.92%
5.24%
6.31%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
519,517
589,412
- -
- -
2,329,861
2025
- -
- -
- -
- -
2,468,892
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
142.59
56.04
- -
- -
633.76
2025
- -
- -
- -
- -
685.06
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
60.64
2.14
- -
- -
123.31
2025
- -
- -
- -
- -
133.89
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Makoto Inoue
Full Time Employees
35,338
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
2-9 Kanda-Tsukasamachi Tokyo Japan 101-0048
IPO Date
Aug 3, 2012
Website
otsuka.com
Similar Companies
Beijing Biostar Pharms Co Ltd (2563.HK)
Chugai Pharmaceutical Co., Ltd. (4519.T)
AstraZeneca PLC (AZN)
Citius Oncology, Inc. (CTOR)
Metacare Co., Ltd. (118000.KS)
Psyence Group Inc. (PSYG.CN)
Business
Otsuka Holdings Co., Ltd. operates as a holding company overseeing a global group engaged in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops and markets pharmaceutical products in psychiatry, neurology, oncology, cardiovascular and renal systems, digestive systems, ophthalmology, diagnostics, intravenous solutions, and medical devices; nutraceuticals and consumer products including Pocari Sweat ion supply drink, Calorie Mate nutritional food, Equelle women's health supplements, Body-mainte conditioning foods and beverages, and OS-1 oral rehydration solution; and other offerings such as soft drinks, wines, functional foods, clinical testing equipment, cosmetics, chemical products including hydrazine and potassium titanate, IT solutions, bio-pesticides, infusion and clinical nutrition products, stable isotopes, and polyolefin foams. Founded in 1921 with the holding company established in 2008, Otsuka Holdings is headquartered in Tokyo, Japan, with principal operations in Japan, the United States, Europe, and Asia. Recent developments include the acquisition of Jnana Therapeutics Inc. in 2024 to bolster its pipeline in phenylketonuria and autoimmune diseases through Otsuka America Inc., the formation of a joint venture with ICU Medical Inc. in late 2024 for North American IV solutions manufacturing effective early 2025 under Otsuka Pharmaceutical Factory, and the submission of a new drug application to the U.S. FDA in November 2025 for centanafadine to treat ADHD in children.

Company News

APIChat

  • seekingalpha.com

    Aristotle International Equity ADR WM Q1 2026 Contributors And Detractors

  • seekingalpha.com

    Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript

  • seekingalpha.com

    Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript

  • defenseworld.net

    Otsuka (OTCMKTS:OTSKF) Trading Up 3% – Should You Buy?

  • reuters.com

    US FDA approves Otsuka's kidney disease drug

  • seekingalpha.com

    Otsuka Corporation (OSUKF) Q1 FY2025 Earnings Call Transcript